Blog
RSS FeedPosted by Michael Wonder on 14 Feb 2019
Determining value in health technology assessment: stay the course or tack away?
15 February 2019 - The economic evaluation of new health technologies to assess whether the value of the expected health benefits ...
Posted by Michael Wonder on 10 Feb 2019
Patient involvement in reflective multi-criteria decision analysis to assist decision making in oncology
7 February 2019 - Patient involvement in drug evaluation decision making is increasing. ...
Posted by Michael Wonder on 23 Apr 2018
Cost-effectiveness thresholds: the past, the present and the future
23 April 2018 - Cost-effectiveness (CE) thresholds are being discussed more frequently and there have been many new developments in this ...
Posted by Michael Wonder on 18 Apr 2018
The use of MCDA in HTA: great potential, but more effort needed
18 April 2018 - The potential for multi-criteria decision analysis (MCDA) to support health technology assessment (HTA) has been much discussed, ...
Posted by Michael Wonder on 13 Apr 2018
Decision components of NICE's technology appraisals assessment framework
10 April 2018 - The UK's NICE is an established health technology assessment agency. de Folter et al. present a ...
Posted by Michael Wonder on 21 Mar 2018
Using real world data in health technology assessment (HTA) practice: a comparative study of five HTA agencies
21 March 2018 - This study examines whether real world data is incorporated in health technology assessment (HTA) of melanoma drugs ...
Posted by Michael Wonder on 20 Feb 2018
Beyond QALYs: multi-criteria based estimation of maximum willingness to pay for health technologies
20 February 2018 - The QALY is a useful outcome measure in cost-effectiveness analysis. But in determining the overall value of ...
Posted by Michael Wonder on 20 Feb 2018
The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States: relationship to cost-effectiveness analysis and methodological challenges
20 February 2018 - Good practices for budget impact analysis have been increasingly developed since the year 2000. ...
Posted by Michael Wonder on 23 Jan 2018
Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
23 January 2018 - Although health technology assessment systems base their decision making process either on economic evaluations or comparative clinical ...
Posted by Michael Wonder on 30 Oct 2017
Predictive validation and the re-analysis of cost-effectiveness: do we dare to tread?
30 October 2017 - Predictive validation (also known as fourth-order validation) involves the comparison between model outputs and observed data ...
Posted by Michael Wonder on 16 Oct 2017
Social value and individual choice: the value of a choice-based decision-making process in a collectively funded health system
4 October 2017 - Evidence about cost-effectiveness is increasingly being used to inform decisions about the funding of new technologies that ...
Posted by Michael Wonder on 09 Oct 2017
Time for a change in how new antibiotics are reimbursed: development of an insurance framework for funding new antibiotics based on a policy of risk mitigation
9 October 2017 - Healthcare systems depend on the availability of new antibiotics. ...
Posted by Michael Wonder on 27 Sep 2017
New advance value framework offered as a decision-support tool for reimbursement
25 September 2017 - Researchers at the London School of Economics and Political Science have developed a multiple criteria decision ...
Posted by Michael Wonder on 11 Sep 2017
NICE: We're the institute of 'yes'
11 September 2017 - But Meindert Boysen says affordability conversations with pharma need to happen earlier. ...
Posted by Michael Wonder on 24 Jul 2017
Managing conflicts of interest – making good decisions
24 July 2017 - NICE is seeking views on a new conflicts of interest policy to ensure its committees’ decisions ...